Korean J Intern Med.  2015 Nov;30(6):759-770. 10.3904/kjim.2015.30.6.759.

Role of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantation

• Lim SW
• Jin JZ
• Jin L
• Jin J
• Li C

• KMID: 2381580
• DOI: http://doi.org/10.3904/kjim.2015.30.6.759

Abstract

Despite strict pre- and post-transplantation screening, the incidence of new-onset diabetes after transplantation (NODAT) remains as high as 60%. This complication affects the risk of cardiovascular events and patient and graft survival rates. Thus, reducing the impact of NODAT could improve overall transplant success. The pathogenesis of NODAT is multifactorial, and both modifiable and nonmodifiable risk factors have been implicated. Monitoring and controlling the blood glucose profile, implementing multidisciplinary care, performing lifestyle modifications, using a modified immunosuppressive regimen, administering anti-metabolite agents, and taking a conventional antidiabetic approach may diminish the incidence of NODAT. In addition to these preventive strategies, inhibition of dipeptidyl peptidase-4 (DPP4) by the gliptin family of drugs has recently gained considerable interest as therapy for type 2 diabetes mellitus and NODAT. This review focuses on the role of DPP4 inhibitors and discusses recent literature regarding management of NODAT.

Keyword

Kidney transplantation; New-onset diabetes after transplantation; Dipeptidyl-peptidase IV inhibitors

MeSH Terms

Animals
Blood Glucose/drug effects/metabolism
Diabetes Mellitus/diagnosis/*drug therapy/enzymology/etiology
Dipeptidyl Peptidase 4/*metabolism
Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use
Humans
Organ Transplantation/*adverse effects
Risk Assessment
Risk Factors
Treatment Outcome
Blood Glucose
Dipeptidyl-Peptidase IV Inhibitors
Dipeptidyl Peptidase 4